Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Virpax Pharmaceuticals Inc (NQ: VRPX )

0.8369 +0.0369 (+4.61%)
Streaming Delayed Price Updated: 1:12 PM EDT, Sep 12, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Virpax Pharmaceuticals Inc

< Previous 1 2 3 Next >
Virpax Pharmaceuticals Reports 2024 Second Quarter Results and Recent Developments
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Virpax Pharmaceuticals to Present at Sidoti Virtual Investor Conference August 14-15
From Virpax Pharmaceuticals
Via Business Wire
Virpax Regains Compliance with Nasdaq Minimum Bid Price
From Virpax Pharmaceuticals
Via Business Wire
Virpax Announces Positive Results of Swine Model Pilot Study for Probudur™
From Virpax Pharmaceuticals
Via Business Wire
Virpax Pharmaceuticals Secures $2.5 Million Loan Financing and an Agreement with an Institutional Investor to Negotiate Additional Funding
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Virpax® Pharmaceuticals to Present at 2024 BIO International Convention
From Virpax Pharmaceuticals
Via Business Wire
Virpax Announces Pricing of $2.25 Million Public Offering
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Virpax Pharmaceuticals Reports 2024 First Quarter Results and Recent Developments
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Virpax Announces Results of Maximum Tolerated Dose Study for Probudur™
From Virpax Pharmaceuticals
Via Business Wire
Virpax Pharmaceuticals Reports 2023 Year-End Results
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Virpax Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Price
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Virpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc.
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Virpax Pharmaceuticals Announces Preliminary Results of ProbudurTM Pilot Study with the U.S. Army Institute of Surgical Research
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Virpax Pharmaceuticals Announces Results of Special Shareholders Meeting
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Virpax Pharmaceuticals Announces Notification from Nasdaq Related to Delayed Form 10-Q Filing
From Virpax Pharmaceuticals
Via Business Wire
Virpax Pharmaceuticals Announces Leadership Transition
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Virpax Pharmaceuticals Reports 2023 Third Quarter Results and Recent Developments
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Virpax Pharmaceuticals Announces that Envelta™ Remains on Track for Trial in Humans Following FDA Review
From Virpax Pharmaceuticals
Via Business Wire
Virpax Pharmaceuticals Announces Extension of CRADA with the U.S. Army Institute of Surgical Research
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Gerald W. Bruce Appointed President and CEO of Novvae™ Pharmaceuticals
From Virpax Pharmaceuticals
Via Business Wire
Virpax Pharmaceuticals Announces Results of Probudur™ Dose Escalation Studies
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Virpax Pharmaceuticals to Present at the LD Micro Main Event XVI
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Altasciences Chosen by Virpax to Support the Development of a New Drug to Prevent Spread of Flu-like Viruses
From Altasciences
Via Business Wire
Virpax Pharmaceuticals Announces the Formation of Novvae™ Pharmaceuticals
From Virpax Pharmaceuticals
Via Business Wire
Virpax Pharmaceuticals Updates on Litigation
From Virpax Pharmaceuticals
Via Business Wire
Virpax® Pharmaceuticals to Present at H.C. Wainwright 25th Annual Global Investment Conference
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Virpax Pharmaceuticals Reports 2023 Second Quarter Results and Recent Developments
From Virpax® Pharmaceuticals, Inc.
Via Business Wire
Virpax Pharmaceuticals Files Provisional Patent Application for NSAID Formulation and Method
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Virpax Pharmaceuticals, Inc. to Ring NASDAQ Closing Bell on July 24, 2023
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Virpax Pharmaceuticals Files Provisional Patent Application for Intranasal Delivery
From Virpax Pharmaceuticals
Via Business Wire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.